

is high time to realize that the way medicine is practised depends on our own conduct. If we truly believe in basic unalienable principles, we have no choice but to act upon them. *Salus aegroti suprema lex* — the welfare of the patient should be the ultimate goal of our professional services. Then, state and private health care could peacefully coexist because both would have the welfare of patients in mind.

Wilhelm Keyes
Retired Physician
Winnipeg, Man.

REFERENCES

1. Is medicine still a profession? [editorial]. *CMAJ* 2006;174(6):743.
2. Kondro W. Copeman clinics come under scrutiny. *CMAJ* 2006;174(6):753.
3. Kondro W, Sibbald B. Tony Clement appointed as Canada's new health minister. *CMAJ* 2006;174(6):754.

DOI:10.1503/cmaj.1060079

CMAJ's editorial on the topic of whether medicine is still a profession¹ states that the core values of the medical profession are integrity, compassion, altruism and excellence, but in my view these values have eroded over the past few decades.

For example, the most visible characteristic of modern medicine is excellence, but this quality is seen by the profession and the public alike as mere technical achievement. The practising physician relies heavily on positive PR from this cutting-edge image, and each media account of a medical breakthrough is a welcome ray of sunshine in the progressively dimming world of what is now recognized as the "sickness industry."

People have discovered that doctors are people, too — wealthy ones, more often than not. People have also discovered that if you poke any saint deep enough, you will soon touch self-interest. There goes the aura of altruism and compassion.

The editorial says that we need to "restore the scientific integrity of medicine." Perhaps we would be well advised to work on the personal integrity of individual doctors, since so many of them have found a new home in the deep pockets of Big Pharma.

The word "humane" has disappeared from many sectors of society, including medicine. This concept needs to be brought back to replace the devils of indifference and greed. As additional reading on this subject, I highly recommend Petr Skrabanek's *The Death of Humane Medicine and the Rise of Coercive Healthism*.²

Herbert H. Nehrlich
Private Practice
Bribie Island, Australia

REFERENCES

1. Is medicine still a profession? [editorial]. *CMAJ* 2006;174(6):743.
2. Skrabanek P. *The Death of Humane Medicine and the Rise of Coercive Healthism*. Social Affairs Unit, London, UK 1994.

DOI:10.1503/cmaj.1060082

Patient characteristics not described

Research based on administrative databases, such as that reported by Scot Simpson and associates,¹ who investigated the dose-response relation between sulfonylurea drugs and death in a patient with type 2 diabetes mellitus, can demonstrate trends but may not provide sufficient detail about individual patient variables. In treating new-onset diabetes, many physicians might be expected to initially prescribe metformin for obese patients and glyburide for patients of normal weight.² However, the research reported by Simpson and associates does not allow us to confirm or refute such possible trends. Is the greater mortality rate associated with glyburide partially attributable to the more severe insulin deficiency seen in normal-weight diabetic patients, rather than being related to the type of antidiabetic drug used?

Simpson and associates did not determine mortality rates for patients receiving dual metformin and glyburide therapy. Thus, there was no opportunity to observe any possible protective effect of combined therapy.

At a more practical level, this study may convince physicians to switch to other, less common sulfonylureas or thiazolidinediones. However, many pa-

tients covered by provincial drug plans may have limited access to payment for such drugs. Provincial drug programs will need to move quickly to accommodate such shifts in prescribing practice to avoid financial pressures on our patients.

Stanley Lofsky
Family Physician
Toronto, Ont.

REFERENCES

1. Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. *CMAJ* 2006;174(2):169-74.
2. Cheng AYY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. *CMAJ* 2005;172(2):213-26.

DOI:10.1503/cmaj.1060078

Corrections

A sentence in the Results section of the abstract on page 1421¹ accidentally reversed the intended meaning of the data comparison for the primary end points of the study. It should read, "Results: The efficacy end point (a composite of 30-day mortality, reinfarction or refractory ischemia) was 12.2% with enoxaparin versus 16.0% with unfractionated heparin ($p < 0.001$); the combined end point of efficacy plus safety (a composite of 30-day mortality, reinfarction, refractory ischemia, intracranial hemorrhage [ICH] or major systemic bleeding) was 15.0% versus 18.0%, respectively ($p = 0.003$)."

REFERENCE

1. Armstrong PW, Chang WC, Wallentin L, et al. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. *CMAJ* 2006;174(10):1421-6.

DOI:10.1503/cmaj.060639

In the obituary notice for Dr. Harald Stolberg, his date of death was mistakenly listed as 84.¹ The doctor died at age 79.

REFERENCE

1. Deaths. *CMAJ* 2005;172(13):1755.

DOI:10.1503/cmaj.060640